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Long-Term Protection from Bovine Viral Diarrhea Virus
in Feedlot Cattle
C.C.L. Chase,' J. Hans~n,~
T. Fra~er,~
L.Bra~n,~
S. Ander~on,~
and D.J. Hurley
Departments of Veterinary Science and Biology/Microbiology

SDSU

CAllLE 96-9
Summary

Bovine viral diarrhea virus (BVDV) causes
respiratory and reproductive disease.
The
duration of immunity of an inactivated vaccine
(Virashield 5: Grand Laboratories, Freeman, SD)
was measured in t w o challenge studies. In both
studies the vaccinated animals demonstrated
fewer clinical signs when challenged w i t h Type
II BVDV at 1 1 or 1 3 months post vaccination.
These results indicate that an inactivated
vaccine administered properly can protect
animals against disease up t o at least a year
post vaccination.
Key Words: Bovine viral diarrhea virus, BVDV,
Vaccine, Challenge

BVDV vaccines have traditionally been
either modified live virus (MLV) or inactivated
viruses. MLV vaccines have been touted o n
their ability t o produce cell immunity and t o
have a longer duration of action.
This study was designed t o assess the
efficacy and duration of cattle vaccinated w i t h
the inactivated Virashield 5 (Grand Laboratories,
Freeman, SD) by challenging the animals w i t h
BVDV. This report details the results of these
clinical trials.
Materials and Methods
Animals
Trial 1

Introduction
Bovine viral diarrhea virus (BVDV) has
emerged as the major viral disease of cattle.
BVDV is the predominant virus isolated from
bovine respiratory disease (BRD) and from
abortions at the Animal Disease Research and
Diagnostic Laboratory at South Dakota State
University.
BVDV was isolated from 1 0 0
submissions and represented 8 9 % of all BRD
viral isolations made i n 1995. T w o biotypes of
BVDV virus have been recognized. Type I BVDV
is the major type that has been responsible for
most clinical BVDV in South Dakota. Type II
BVDV has emerged i n several areas of the
country and has been implicated in acute BVDV
outbreaks.

Vaccinates. Six crossbred calves (Charolais
cross, 500-750 Ib) seronegative for BVDV were
vaccinated in June 1 9 9 4 w i t h 5 m l of
Virashield 5 intramuscular. A second dose was
administered 1 month later.
Control. Three crossbred calves (Charolais
cross, 400-500 Ib) seronegative for IBR, BVDV,
and BRSV were used as controls.
Trial 2
Vaccinates. Six yearling calves (Holstein
cross, 1 100-12 0 0 Ib) seronegative for BVDV
were vaccinated in October of 1994. The
animals were injected w i t h 5 m l of Virashield 5
intramuscular. A second dose was administered
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one month later.
In November 1995, the
animals were moved t o the Department of
Veterinary Science, South Dakota State
University.

beginning 3 days prior t o challenge and
continued until 1 4 days post infection.
Statistical analysis was done using a student
T-test with significance cutoff of 0.05.

Control. Three yearling calves (Holstein
cross, 1 100-12 0 0 Ib) seronegative for BVDV
were used as controls.

Clinical Diarrhea Sians-BVDV.
Fecal
consistency was measured beginning 3 days
prior to challenge and continued until 1 4 days
post infection in the BVDV challenge. The
scoring system was 0 = normal consistency; 1
= loose consistency, and 2 = watery
consistency. Statistical analysis was done using
a student T-test with significance cutoff of
0.05.

Challenge

m.

The BVDV challenge virus was from
the National Veterinary Service Laboratory,
Ames, IA. The challenge vials were labeled
"NVSL BVD Challenge Virus (890) Lot# 94-9.
The challenge upon dilution with 2.8 ml of
diluent was lo7.' tissue culture infectious dose
5 0 (TCID 50:the amount of virus required t o kill
5 0 % of the cells) per animal.
Virus Inoculation

Seroloau. Blood samples were drawn from
all animals in each challenge. The samples were
drawn prior t o infection and at -2, 5, 12, and
26 days post infection. Serum was harvested
and stored at -70" C. The serum was shipped
to Grand Laboratories, Larchwood, IA, for serum
neutralization testing.

Trial 1
Results and Discussion
Nine animals were challenged 11 months
following the first vaccination with the BVDV
virus inoculum described above. Each calf was
swabbed prior t o challenge, 2 ml per nostril
( 4 ml total) of inoculum was administered with
an atomizer in each nostril and the calves were
swabbed for virus isolation post inoculation.
Trial 2
Nine animals were challenged 1 3 months
following the first vaccination with the BVDV
virus inoculum described above. Each calf was
swabbed prior t o challenge, 2 ml per nostril
( 4 ml total) of inoculum was administered with
an atomizer in each nostril, and the calves were
swabbed for virus isolation post inoculation
Testing Procedures

Clinical Res~iratorv Sians and
Tem~erature. During each challenge, animals
were observed daily for clinical signs beginning
3 days prior t o challenge and continued until
1 4 days post challenge. The animals were
observed
for
lacrimation,
conjunctivitis,
dyspnea, and nasal discharge and clinical scores
assigned. The basal body temperature was also
measured rectally with a digital thermometer

BVDV Clinical Res~iratoryScores (includes body
temperature)
Trial 1. Prior to challenge, all the cattle had
-a mild serous nasal discharge. A t day 7 post
infection, there was a threefold increase over
pre-challenge scores in the control animals. This
continued out t o day 1 3 post infection. There
was a significant increase (P< .05) in clinical
scores between the t w o groups on days 8 t o 1 3
of the BVDV experiment (Figure 1).
Trial 2. Prior to challenge, all the cattle had
a mild serous nasal discharge. There was no
difference in the clinical signs between the t w o
groups. On days 7 and 8 post challenge, the
controls had higher scores, but there was no
clear trend. The body temperatures in these
groups did not vary much. On days 8 and 9,
the controls had temperatures 2 " higher than
the vaccinates (data not shown).
Clinical Diarrhea Scores BVDV
Trial 1. Fecal consistency was similar for
both groups prior t o challenge and up t o day 7
post infection (Figure 2). On days 8, 10, and

11, there was a significant increase ( P < .05)in
diarrhea i n the control animals (Figure 2).

representative of the serological response in
Trial 2 against either Type I or Type II BVDV.

Trial 2. There was no difference in fecal
scores between the t w o groups (data not
shown).

These results indicate that vaccination w i t h
a properly administered inactivated vaccine can
result in protection of feeder cattle from
challenge w i t h BVDV Type II over a year after
vaccination.
Respiratory disease in feedlot
cattle continues t o be a serious problem in the
cattle industry. One of the important questions
yet t o be answered concerns the protection of
c o w s against fetal BVDV infection.
This
infection results in abortions and BVDV
persistently infected calves in the herd. These
persistently infected animals maintain the virus
i n the herd and are a threat t o even well
vaccinated animals. Future studies are planned
t o answer these questions.

Seroloav

.
Vaccinated animals developed
BVDV serum titers that peaked 2 t o 3 months
following the first vaccination (Figure 3).
Figure 3 is representative of the serological
response i n Trial 1 against either Type I or
Type II BVDV. Following infection, the serum
titers o f the vaccinated animals reached very
high levels compared t o the controls.
Trial 2. The serological response was
similar t o Trial 1 (Figure 4).
Figure 4 is
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Figure 1. Bovine Viral Diarrhea Virus Clinical Scores
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Figure 2. Diarrheal Scores following BVDV lnfection
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Figure 3. BVDV-Trial 1 Serum Neutralization Titers
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Figure 4. BVDV-Trial 2 Serum Neutralization Titers

